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Summary.-Injections of thymic extract (TE), TE primed lymphocytes or normal
lymph node cells were effective in bringing about total remission of the Dunning
leukaemia in inbred Fisher CD rats. Survival greater than 365 days occurred in
10-80o, of the various treated groups whereas untreated leukaemic rats, or leukaemic
rats treated with spleen " mock thymus extract " or bovine serum albumin, died
within an average of 10-17 days. Administration of antilymphocyte serum into
leukaemic rats enhanced their death rate. Stimulation of cell mediated immunity
via the production of functional thymus stimulated lymphocytes is postulated as the
mechanism by which tumour rejection occurred.
THYMUS mediated immune surveil-
lance has been indicated as an important
mechanism in protecting the host from
cancers arising fromthereticuloendothelial
system (Burnet, 1970; Good and Finstad,
1969; Hollinshead, Glew and Bunnag,
1970; Eilber and Morton, 1970). The
effectiveness ofthymic hormones in stimu-
lating immune recognition and elimina-
tion of cancers arising in the reticulo-
endothelial system is unknown.
In 1966 Goldstein, Slater and White
described a dialyzable glycoprotein extract
obtained from calf thymus which they
labelled thymosin. In vivo studies indi-
cated that this thymic extract (Fraction
3) enhanced allograft rejection, restored
immunological competence of neonatally
thymectomized mice, reduced the inci-
dence of wasting disease and was partially
effective in developing resistance to virus
induced murine sarcoma tumours (Hardy
et al., 1968; Law, Goldstein and White,
1968; Asanuma, Goldstein and White,
1970; Zisblatt et al., 1970).
In vitro studies by Bach et al. (1971)
have indicated that thymosin induces
differentiation of primitive cells of bone
marrow origin (B cells) into long lived
lymphocytes bearing theta antigen (T
cells). Incubation of B cells with thy-
mosin has been shown to produce a new
population of lymphoid cells with sensi-
tivity to azathioprine, antilymphocyte or
antitheta sera.
Miller, Schmiege and Rule (1973) have
shown that thymic extracts (TE) could
substitute for the presence of T cells in
synergistic collaboration with B cells in
the humoral antibody response to sheep
erythrocytes. These studies indicated
that TE induced functional T cell activity.
In this study the same thymic extract
was administered to inbred Fisher-CD
rats carrying a syngeneic monocytic
leukaemia initially discovered by Dunning
and Curtis in 1957. Syngeneic lymphoid
cells derived from this same line or hetero-
logous antithymocyte serum were also
administered to leukaemic rats to investi-
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gate changes in mean survival time in
these animals. The purpose of this in-
vestigation was to augment rejection or
acceleration of the Dunning leukaemia
with known modalities and thymic extract
to alter thymic-derived lymphocyte im-
mune response.
MATERIALS AND METHODS
Fresh calf thymus and spleen were ob-
tained from a local slaughterhouse, cleaned,
defatted and connective tissue removed.
Thymus extract (Fraction 3) prepared
according to Goldstein et al. (1966) was
lyophilized within 24 hours and stored at
- 20°C for later use. "Mock " thymic
extract was prepared from spleen by the same
procedure. WVater used in all procedures was
first run through 5 0 and 0 45 ,um filters, 2
deionizing columns and a charcoal bed. This
treatment rendered the water free of ions
and bacterial contamination. These prepar-
ations did not contain endotoxin, nor
conversely could endotoxin substitute for
thymic extract in the synergistic collabora-
tion studies.
Inbred leukaemic Fisher-CD rats (150 g)
were obtained from the Arthur D. Little Co.
of Cambridge, Mass. This company main-
tains the Dunning leukaemia by 2 methods.
One includes the weekly passage of 105 cells
in 0-1 ml of saline injected intraperitoneally
as the ascites tumour. Cells were also
maintained from much earlier passages
frozen in 5% glycerine containing Eagle's
basic medium and 20% foetal calf serum at
- 100°C in the tumour bank. Normally the
ascites tumours were passaged in our own
laboratory for at least 2-4 passages in Fisher-
CD rats whence leukaemic cells were obtained
from either current or frozen cell passage.
Fisher-CD rats obtained from the Charles
River Breeding Laboratories were fed purina
chow and water ad libitum. Peritoneal fluids
obtained from leukaemic rats were washed
3 times in saline at 1500 rev/min in an inter-
national clinical centrifuge. Leukaemic cell
counts were determined by the methods
described by Todd, Sanford and Wells (1957),
and 104 per ml of these cells were transferred
to new hosts by intraperitoneal injections in
all experimental animal groups.
Intravenous TE therapy was administered
to 60 rats (10/group) according to the
following schedule: one group received 5
mg/day of buffered TE, pH 7-2, Day -3 to
Day 0; another, 5 mg TE/day from Day -3
to Day +4; and the last group 5 mg TE/day
from Day +1 to Day -[4. The fourth group
of leukaemic rats not treated with TE
received 0 5 ml of unabsorbed rabbit anti-rat
thymocyte serum from Day -3 to Day -1
and 0-25 ml of absorbed rabbit anti-rat
thymocyte serum from Day 0 to Day +4. A
control group received 5 mg of spleen " mock
TE " per day from Day +1 to Day +4. All
experimental groups, including the non-
treated control group, received 104 leukaemic
cells/rat on Day 0. Experiments were
repeated twice. Survival rates ofrats within
each group were determined. These are
shown in Table I.
TE primed lymphoid cells were obtained
by injecting 1 ml of 15 mg/ml buffered
TE/rat intravenously into a group of 9 rats.
Each rat received one injection every 48 hours
for a total of3 injections. Twenty-four hours
after the last injection the rats were sacrificed.
The thymus, spleen and mesenteric lymph
nodes from TE treated rats were removed.
Untreated rats were also sacrificed and
thymus, spleen and mesenteric lymph nodes
were similarly obtained. These were washed
in saline, cut into small pieces, homogenized
gently by hand and the homogenate sieved
through cheese cloth before spinning at 2000
rev/min for 10 min in an international
clinical centrifuge. The packed cells ob-
tained were made up to a total volume of5 ml
in tris buffer. The concentration of white
blood cells was determined as described by
Todd et al. (1957). Cell concentrations were
adjusted to approximately 108 cells/ml for
use the same day.
All rats received 104 Dunning leukaemia
cells on Day 0. On Day 1 different groups
of 10 rats received intravenous injections of
108TEprimedlymphnodecells, normallymph
node cells, TE primed spleen cells, normal
spleen cells, TE primed thyrnus cells, normal
thymus cells or saline.
Leukaemic rats receiving treatment were
considered to have obtained complete remis-
sion from cancer if their survival time was
365 days or better, counting from Day 0 of
the experiment. Many survived over 2
years. The method of Bancroft (1965) was
used whenever possible to, assess values and
the significance ofthe results obtained.BAN AN KHAW AND A. H. RULE
TABLE I.-Survival Rates of Rats Bearing the Dunning Leukaemia: Effect of Intravenous
Thymic Extract Therapy
No. of No. of
Group rats experiments
Treatment given
to each rat
1 10 5 None
2 10 3 Thymic extract
5 mg/day
Day -3 to O
3 10 3 Thymic extiact
5 mg/day
Day-3 to +4
4 10 : Thymic extract
5 mg/day
Day +I to +-4
5 10 2 Rabbit anti-rat, thymocyte
serum* 0-5 ml/day
(Day -3 to -1)t an(d
0-25 ml/day (Day 0 to
-4):
6 10 2 Spleen " mock TE"
5 mg/clay (Day + I to + 4)
* No thymosini administere(l.
t Unabsorbed rabbit anti-rat thymocyte seruim. I Absorbed rabbit anti-rat thymocyte serum.
Uf)
n
LL
0
m
z
U(
9
8
7
6
5
4
3
2
Mean survival
time (days)
15-7
J) %0 Remission
value (at 1 year)
0
40
50
60
13-2
17-4
0-04
0-1
0
0
2 6 10 14 18 22 26 90
SURVIVAL IN DAYS
Fic. 1.-Survival of rats with Dutnininig leukaemia contraste(l with thymosin treate(d ami(i rabbit anti-rat
lymphocyte serum tieate(d letikaemic rats.
RESULTS
In Table I it is shown that untreated
leukaemic control rat groups died within
3 weeks whereas 60% of those receiving
TE after the inducing dose of 104 leu-
kaemic cells/rat treatment from Day +1
to Day +4 obtained complete remission.
Rats that received treatment from Day
-3 to Day + 4 had better complete
remission rates than those that received
TE treatment from Day -3 to Day 0.
Rats receiving rabbit anti-rat thymocyte
serum were more susceptible to Dunning
leukaemia than the leukaemic controls
(P < 0.04).
Injections of either bovine serum
albumin or spleen " mock TE " in leukae-
mic rats produced death rates statistically
similar to those for the uninjected leu-
kaemic rats. Young rats under 100 g or
290
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TABLE II. Survival Rates of Rats Bearing the Thunning Leukaemia: Effect of Lymphoid
Cell Replacement Therapy
2
3
4
6
7
No. of
rats
10
10
10
10
10
10
10
Treatmeint 30 houirs afterI 104
letukaemic cells
NonIe
107 Normal lymph niodle cells/rat
107 TE primed lymph no(de cells rat
108 Normal spleen cells/rat
108 TE primed spleen cells/rat
108 Normal thymus cells/rat
108 TE primedl thymus cells/rat
3 weeks of age were not responsive to TE
treattment, nor was the intraperitoneal
route as effective as the intravenous one
used in this study (unpublished data).
The survival rates of rats receiving
lymphoid cell replacement treatment are
shown in Table II. Normal lymph node
cells increased the resistance of rats bear-
ing the Dunning leukaemia but the effect
was somewhat less pronounced than that
observed when leukaemic rats received TE
primed lymph node cell replacement
therapy. Normal spleen cells and normal
thymus cells were not as effective as TE
treated spleen cells or TE primed thymus
cells. However, the results in these
groups of rats receiving normal spleen
cells, normal thymus cells, TE primed
spleen cells and TE primed thymus cells
were inconsistent.
DISCUSSION
Thymic extracts contained in Fraction
3 thymosin have previously been reported
by Hardy et al. (1968) to enhance cell
mediated immunity andallograftrejection.
Evidence for increased resistance to Molo-
ney virus induced sarcoma with thymosin
treatment was also reported by Zisblatt et
al. (1970). The present investigation
suggests that intravenously injected thy-
mic extract (TE) was able to bring about
certain percentages of tumour rejections
in rats carrying a lethal leukaemia. The
results suggested that optimal effective-
ness of TE therapy in rendering complete
remission from cancer depended upon the
time treatment was started. Leukaemic
rats receiving 5 mg TE per rat per day
from Day +1 to Day +4 showed the best
AMean survival
time (dcays)
9 6
9-6
12 -5
10-6
00 Remission
P (one year)
0
10
.30 0-7
0*1
0-05
0
0
0
10
TE induced tumour remission rate. Fur-
ther experimentation would be needed to
establish these data firmly, however.
Rats that received rabbit anti-rat
thymocyte serum (ATS), an immuno-
suppressive agent (Taub, 1970) had an
average survival time of only 13-2 days,
compared with a mean survival time of
15 8 days in untreated controls. The
mode of action of antithymocyte serum is
generally considered to be that of re-
moving or rendering ineffective thymus
derived lymphocytes. Enhancement of
the death rate in the ATS group suggests
that T cell elimination augmented the
carcinogenic response. Conversely, tu-
mour rejection in rats receiving lympho-
cytes, TE stimulated lymphocytes or
tumour extract indicates the possibility
that rejection was the result of enhanced
cell mediated immunity. Studies using
this same thymosin batch in synergistic
collaboration with B cells suggest that the
production of functional T cells enhanced
recognition and elimination of the leukae-
mic cell population (Miller et al., 1973).
Thymus mediated immune surveil-
lance in cancers of the reticuloendothelial
system have been shown to be of great
importance (Burnet, 1970; Good and
Finstad, 1969). Prehn (1971), however,
has questioned the importance of immune
surveillance in tumours of other tissues
and organs. Indeed, the relationship of
these findings to human carcinogenesis
remains obscure, although the importance
of immunological therapy in the treat-
ment of human leukaemia has already
been indicated by Mathe et al. (1969).
Whether or not thymic hormones will be292 BAN AN KHAW AND A. H. RULE
more effective than B.C.G. in human
immunotherapy of cancer remains open
to investigation.
The importance of thymic enhanced
cellular immunity or lymphocyte replace-
ment therapy in the rejection ofleukaemia
in this study is certainly suggested. Data
obtained in this investigation strengthen
the concept of the endocrine function of
the thymus gland as well as thymus
derived lymphocytes in the development
of cell mediated immunity.
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